PHC secures exclusive rights to MaxCyte ExPERT in Japan

The Biomedical Division of PHC Corporation, a subsidiary of PHC Holdings Corporation announces it has signed an exclusive agreement with MaxCyte, Inc. to distribute the MaxCyte ExPERT platform in Japan. In Singapore, SciMed (Asia) Pte Ltd, a subsidiary of PHCHD, separately entered into an exclusive distribution agreement with MaxCyte and launched the ExPERT platform in the country in June. MaxCyte is a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics. Under this partnership, PHCbi will offer sales and service support for MaxCyte’s instruments, consumables, and solutions, providing researchers and manufacturers with access to a clinically proven, non-viral cell engineering platform.

MaxCyte’s ExPERT instrument portfolio is the next generation of leading, clinically and commercially validated electroporation technology for complex and scalable cell engineering. By enabling high transfection efficiency and cell viability, seamless scalability and enhanced functionality, the ExPERT platform delivers the high-end performance essential to enabling the next wave of biological and cellular therapeutics.

PHCbi will distribute and support the full range of MaxCyte platforms covered under this agreement, including the ExPERT ATx®, ExPERT STx®, ExPERT GTx® and ExPERT VLx® as well as related consumables such as processing assemblies and electroporation buffers. These platforms are used by researchers worldwide and have been referenced in more than 70 clinical programs as of Q1 2025.

Also Read: PRD Therapeutics Begins First Human Trial for PRD001

Chikara Takauo, Director of PHC Corporation and General Manager of PHCbi, commented: “We are pleased to add the MaxCyte’s ExPERT instruments to our cell culture technology portfolio. Guided by our vision of ‘contributing to the evolution and progress of therapeutic modalities,’ we are committed to expanding new solutions that address the challenges of QCD (Quality, Cost, and Delivery) in cell and gene therapy (CGT) manufacturing processes. The addition of MaxCyte’s ExPERT portoflio allows us to better support scientists and cell therapy developers by providing them with a powerful, non-viral tool to advance their cell-based research and development processes and ultimately accelerate the adoption of CGT.”

The addition of MaxCyte’s ExPERT platform complements PHCbi’s ongoing efforts to further enhance the efficiency of CGT development and manufacturing processes while improving cell quality and safety. PHCbi recently introduced the LiCellMoTM live-cell metabolic analyzer for research use, incorporating PHC’s core In-Line Monitoring technology. In addition, PHCbi is developing the LiCellGrowTM cell expansion system, which is being designed to optimize the cell culture environment by automatically exchanging culture medium based on the metabolic state of cells. Together with the MaxCyte’s platform, these solutions reflect PHCbi’s commitment to delivering comprehensive support for researchers and developers working in areas such as regenerative medicine, immunotherapy, and bioproduction as well as accelerating cell-based innovation in Japan and Singapore.

SOURCE: BusinessWire